Inventiva S.A. (IVA) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Inventiva Sa.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:03.977 Good morning, good afternoon, everyone, and thank you for joining Inventiva's full year 00:00:03.977 -- 00:00:08.245 2025 financial results and business update. 00:00:08.245 -- 00:00:12.331 Our press release was issued yesterday evening, and this webcast and slides will be available 00:00:12.331 -- 00:00:16.117 in the investor section on our website following the call. 00:00:16.117 -- 00:00:21.546 Joining us on the call today are Andrew Obenshain, Chief Executive Officer, Jean Voletier, 00:00:21.546 -- 00:00:26.314 Chief Financial Officer, and Dr. Jason Campagna, Chief Medical Officer and President 00:00:26.314 -- 00:00:28.077 of R&D. 00:00:28.077 -- 00:00:31.841 I would like to remind everyone that statements made during today's conference call and 00:00:31.841 -- 00:00:36.166 during the Q&A session may include forward-looking statements within the meaning of the 00:00:36.166 -- 00:00:40.210 Private Securities Litigation Reform Act of 1995. 00:00:40.210 -- 00:00:45.356 Please refer to slide two of the slides and our SEC and AMF filings for 00:00:45.356 -- 00:00:50.361 a discussion of associated risks. These statements reflect our views as of today and 00:00:50.361 -- 00:00:54.326 should not be relied upon as representing our views at any later date. 00:00:54.326 -- 00:00:57.727 With that, I will now turn it over to Andrew, starting on slide three. 00:00:57.727 -- 00:00:59.490 Andrew? 00:00:59.490 -- 00:01:03.676 Thank you, David. Good morning, good afternoon to everyone, and thank you for joining 00:01:03.676 -- 00:01:09.124 us. Since joining Inventiva six months ago, I've been struck by the depth of scientific 00:01:09.124 -- 00:01:13.311 conviction behind lanofibrinor and the dedication of this team. 00:01:13.311 -- 00:01:18.899...